ARF6 Inhibitors for Treatment of Acute Lung Injury
ARF6 抑制剂治疗急性肺损伤
基本信息
- 批准号:9347749
- 负责人:
- 金额:$ 88.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:ADME StudyAcinetobacter baumanniiAcute Lung InjuryAdult Respiratory Distress SyndromeAlveolarArea Under CurveBacterial PneumoniaBinding ProteinsBiological AssayBiological SciencesBiological WarfareBlood TransfusionBreathingBurn injuryCanis familiarisCause of DeathCellsChemical Warfare AgentsCleaved cellClinicalDataDevelopmentDoseDrug KineticsEpithelialEstersEtiologyFeedbackFormulationFundingGoalsHepatocyteHospitalsHourHumanIn VitroIncidenceInfectionInflammatoryInflammatory ResponseInjuryIntraperitoneal InjectionsIntravenousLeadLifeLiver MicrosomesLungLysineMeasuresMechanical ventilationModelingMusOrgan failureOryctolagus cuniculusOutcomeOutcome MeasureParentsPathogenicityPermeabilityPersonsPharmacology StudyPhasePlasmaPlasma ProteinsPneumoniaPolymorphProcessProdrugsPropertyProteinsPseudomonas aeruginosaRattusResearch DesignRodentRunningSafetySepsisSepsis SyndromeSodium ChlorideSolubilityStructure of parenchyma of lungTestingTherapeuticTimeToxic effectToxicologyTraumaUnited States National Institutes of HealthVascular SystemViral PneumoniaWateranalytical methodanimal efficacyaqueouscytokinedata sharingexperienceimprovedin vivoinhibitor/antagonistinterestintraperitonealirritationmeetingsmetabolic profilemethod developmentmortalitymouse modelprogramsresponsesafety studyscreeningsmall moleculesmall molecule inhibitortreatment effectwater solubility
项目摘要
PROJECT SUMMARY
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) result from a common pathogenic
process: pulmonary injury or infection triggers an overwhelming inflammatory response (“cytokine storm”) that
results in increased endothelial and epithelial permeability and efflux of inflammatory cells, protein, and water
from the vascular system into the alveolar space. The further release of inflammatory agents from damaged lung
tissue often triggers systemic inflammatory response syndrome (SIRS) and end organ failure, the main cause of
death in ALI/ARDS. ALI and ARDS are precipitated by diverse etiologies including aspiration, inhalation injury,
bacterial and viral pneumonias, trauma, burn injury, blood transfusion, sepsis, and other factors. In fact, biologic
and chemical warfare agents are often selected for their ability to cause the devastating effects of ALI/ARDS.
The incidence of ALI is estimated to be approximately 79 cases per 100,000 person-years. Improvements in
outcome have come about over the past decade due to improved strategies of mechanical ventilation and
advances in general supportive measures. Unfortunately, even today, the treatment for those afflicted remains
largely supportive with a mortality rate of approximately 40%.
Navigen’s objective is to develop a small molecule ARF6 inhibitor as a treatment for ALI/ARDS. In Phase I,
we presented ARF6 as a target for treatment of ALI/ARDS, and we shared data establishing the potential
therapeutic value of inhibiting ARF6 to treat ALI/ARDS. The specific aims of our Phase I application were to
identify a number of ARF6 inhibitors with required potency and solubility, to characterize the pharmacokinetic
(PK) properties of a small number of these compounds, and to obtain convincing in vivo proof-of-concept efficacy
in a mouse model of LPS-induced ALI, exploring both dose-response relationships and time-of-treatment effects.
We accomplished these goals and identified five compounds of interest. Since submitting our Phase II application
in January, 2016, we have made significant progress and have identified a lead candidate, NAV-5093, to carry
forward into Phase II. NAV-5093 is a water-soluble lysine prodrug (dihydrochloride salt) of NAV-4424, itself one
of the leading 5 candidates identified in Phase I. NAV-5093 has the advantage of high water solubility, making it
amenable to formulation for intravenous (IV) administration in the hospital setting for treatment of ALI/ARDS.
NAV-5093 is cleaved rapidly to release parent NAV-4424 in vivo, and is effective in the mouse model of LPS-
induced ALI as well as in Acinetobacter baumannii (AB)-induced pneumonia in neutropenic mice. Over the next
two years in Phase II, we propose to accomplish the following: (1) demonstrate efficacy of NAV-5093 in two rat
models of ALI using accepted outcome measures, (2) characterize the in vitro ADME and in vivo PK properties
of NAV-5093, (3) conduct initial toxicity studies of NAV-5093 in rats, (4) manufacture NAV-5093 and optimize an
aqueous formulation of NAV-5093 for IV administration, and (5) hold a pre-IND meeting with the FDA.
项目摘要
急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS)是由共同的病原体引起的,
过程:肺损伤或感染引发压倒性的炎症反应(“细胞因子风暴”),
导致内皮和上皮渗透性增加以及炎性细胞、蛋白质和水的流出
从血管系统进入肺泡腔。炎症因子从受损肺中的进一步释放
组织经常触发全身炎症反应综合征(SIRS)和终末器官衰竭,
ALI/ARDS死亡。ALI和ARDS由多种病因引起,包括吸入性损伤,吸入性损伤,
细菌性和病毒性肺炎、创伤、烧伤、输血、败血症和其他因素。事实上,生物
并且化学战剂通常因其引起ALI/ARDS的破坏性作用的能力而被选择。
据估计,ALI的发病率约为79例/100,000人年。改善
在过去的十年中,由于机械通气策略的改进,
一般性支助措施的进展。不幸的是,即使在今天,
死亡率约为40%。
Navigen的目标是开发一种小分子ARF 6抑制剂,用于治疗ALI/ARDS。在第一阶段,
我们提出了ARF 6作为治疗ALI/ARDS的靶点,并分享了建立潜在的
抑制ARF 6对治疗ALI/ARDS的治疗价值。我们第一阶段申请的具体目标是
鉴定具有所需效力和溶解度的许多ARF 6抑制剂,以表征药代动力学
(PK)这些化合物的少数性质,并获得令人信服的体内概念验证功效
在LPS诱导的ALI小鼠模型中,探索剂量-反应关系和治疗时间效应。
我们实现了这些目标,并确定了五种感兴趣的化合物。自从提交了我们的第二阶段申请
2016年1月,我们已经取得了重大进展,并确定了一个主要候选人,NAV-5093,携带
进入第二阶段。NAV-5093是NAV-4424的水溶性赖氨酸前药(二盐酸盐),NAV-4424本身是一种
在第一阶段确定的主要5名候选人中。NAV-5093具有高水溶性的优点,
适合于在医院环境中静脉内(IV)给药以治疗ALI/ARDS的制剂。
NAV-5093在体内被快速切割以释放亲本NAV-4424,并且在LPS-4424的小鼠模型中是有效的。
诱导的ALI以及在鲍曼不动杆菌(AB)诱导的肺炎中。在未来
在II期的两年中,我们建议完成以下内容:(1)证明NAV-5093在两只大鼠中的功效
使用公认的结果测量的ALI模型,(2)表征体外ADME和体内PK特性
(3)在大鼠中进行NAV-5093的初始毒性研究,(4)生产NAV-5093并优化其毒性。
IV给药的NAV-5093水性制剂,和(5)与FDA举行IND前会议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN L MUELLER其他文献
ALAN L MUELLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN L MUELLER', 18)}}的其他基金
Depot formulation of a D-peptide HIV entry inhibitor
D 肽 HIV 进入抑制剂的长效制剂
- 批准号:
9408382 - 财政年份:2017
- 资助金额:
$ 88.95万 - 项目类别:
Depot formulation of a D-peptide HIV entry inhibitor
D 肽 HIV 进入抑制剂的长效制剂
- 批准号:
9329767 - 财政年份:2016
- 资助金额:
$ 88.95万 - 项目类别:
Treating Acute Lung Injury via Cytokine Signaling Blockade
通过细胞因子信号传导阻断治疗急性肺损伤
- 批准号:
8905970 - 财政年份:2015
- 资助金额:
$ 88.95万 - 项目类别:
Arf6 inhibitors for the treatment of uveal melanoma
Arf6抑制剂用于治疗葡萄膜黑色素瘤
- 批准号:
8901672 - 财政年份:2015
- 资助金额:
$ 88.95万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
8764703 - 财政年份:2012
- 资助金额:
$ 88.95万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
8467396 - 财政年份:2012
- 资助金额:
$ 88.95万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
8597326 - 财政年份:2012
- 资助金额:
$ 88.95万 - 项目类别:
Slit2N for the Treatment of Viral Hemorrhagic Fever
Slit2N 用于治疗病毒性出血热
- 批准号:
8535980 - 财政年份:2012
- 资助金额:
$ 88.95万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
9466753 - 财政年份:2011
- 资助金额:
$ 88.95万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
9755320 - 财政年份:2011
- 资助金额:
$ 88.95万 - 项目类别:
相似海外基金
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 88.95万 - 项目类别:
Research Grant
Generative machine learning for narrow spectrum antibiotic discovery against Acinetobacter baumannii
生成机器学习用于发现针对鲍曼不动杆菌的窄谱抗生素
- 批准号:
477936 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Operating Grants
Conserved structural dynamics of outer-membrane channels in Acinetobacter baumannii as potential drug targets
鲍曼不动杆菌外膜通道的保守结构动力学作为潜在的药物靶点
- 批准号:
494854 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Operating Grants
Defining key players at the host-pathogen interface during Acinetobacter baumannii infection
定义鲍曼不动杆菌感染期间宿主-病原体界面的关键参与者
- 批准号:
488684 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Operating Grants
Study of clinically over-expressed and chimeric RND multidrug efflux pumps from Acinetobacter baumannii and Pseudomonas aeruginosa
鲍曼不动杆菌和铜绿假单胞菌临床过表达和嵌合 RND 多药外排泵的研究
- 批准号:
23K14346 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
仿生巨噬细胞膜包被的纳米海绵:一种治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌医院相关肺炎的新疗法
- 批准号:
10674406 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Using strain history to improve prediction of the evolution of antimicrobial resistance in Acinetobacter baumannii
利用菌株历史改进对鲍曼不动杆菌抗菌药物耐药性演变的预测
- 批准号:
10677362 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii
鲍曼不动杆菌适应性外排介导的耐药性抑制剂
- 批准号:
10625029 - 财政年份:2023
- 资助金额:
$ 88.95万 - 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10596620 - 财政年份:2022
- 资助金额:
$ 88.95万 - 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10449699 - 财政年份:2022
- 资助金额:
$ 88.95万 - 项目类别: